ネクセラファーマ's ordinary profit forecast for the fiscal year ending December 2026 fell 5.2% week on week to ¥4,768 million, while the rating consensus remained unchanged at 4.7, according to reports. Related stocks cited include アンジェス, サンバイオ, 東和薬品 and JCRファーマ.
The consensus forecast for ネクセラファーマ's ordinary profit for the fiscal year ending December 2026 fell 5.2% from ¥4,988 million the previous week to ¥4,768 million. The rating consensus was also reported to be unchanged at 4.7.
In addition to ネクセラファーマ, the article cited related stocks including アンジェス, サンバイオ, 東和薬品 and JCRファーマ, whose performance was also presented as a focus for investors.
IFIS Japan's view and related information on the stocks concerned were published, together with the latest update times for related news.